FEMASYS INC (FEMY) Stock Fundamental Analysis

NASDAQ:FEMY • US31447E1055

0.55 USD
+0.01 (+1.57%)
At close: Feb 23, 2026
0.5246 USD
-0.03 (-4.62%)
After Hours: 2/23/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

FEMY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of FEMY have multiple concerns. FEMY is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year FEMY has reported negative net income.
  • FEMY had a negative operating cash flow in the past year.
  • In the past 5 years FEMY always reported negative net income.
  • FEMY had a negative operating cash flow in each of the past 5 years.
FEMY Yearly Net Income VS EBIT VS OCF VS FCFFEMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • With a Return On Assets value of -121.55%, FEMY is not doing good in the industry: 83.24% of the companies in the same industry are doing better.
  • FEMY has a Return On Equity of -434.59%. This is amonst the worse of the industry: FEMY underperforms 81.08% of its industry peers.
Industry RankSector Rank
ROA -121.55%
ROE -434.59%
ROIC N/A
ROA(3y)-89.97%
ROA(5y)-77.42%
ROE(3y)-322.97%
ROE(5y)-238.66%
ROIC(3y)N/A
ROIC(5y)N/A
FEMY Yearly ROA, ROE, ROICFEMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

  • FEMY's Gross Margin of 63.05% is fine compared to the rest of the industry. FEMY outperforms 67.03% of its industry peers.
  • In the last couple of years the Gross Margin of FEMY has declined.
  • The Profit Margin and Operating Margin are not available for FEMY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.05%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y-2.71%
FEMY Yearly Profit, Operating, Gross MarginsFEMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • FEMY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for FEMY has been increased compared to 1 year ago.
  • Compared to 5 years ago, FEMY has more shares outstanding
  • FEMY has a worse debt/assets ratio than last year.
FEMY Yearly Shares OutstandingFEMY Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
FEMY Yearly Total Debt VS Total AssetsFEMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

  • Based on the Altman-Z score of -13.30, we must say that FEMY is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -13.30, FEMY is not doing good in the industry: 81.62% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 1.43 is on the high side and indicates that FEMY has dependencies on debt financing.
  • FEMY has a Debt to Equity ratio of 1.43. This is in the lower half of the industry: FEMY underperforms 79.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF N/A
Altman-Z -13.3
ROIC/WACCN/A
WACC9.46%
FEMY Yearly LT Debt VS Equity VS FCFFEMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

  • FEMY has a Current Ratio of 1.16. This is a normal value and indicates that FEMY is financially healthy and should not expect problems in meeting its short term obligations.
  • FEMY has a Current ratio of 1.16. This is amonst the worse of the industry: FEMY underperforms 82.70% of its industry peers.
  • FEMY has a Quick Ratio of 1.16. This is a bad value and indicates that FEMY is not financially healthy enough and could expect problems in meeting its short term obligations.
  • FEMY has a worse Quick ratio (0.61) than 89.19% of its industry peers.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 0.61
FEMY Yearly Current Assets VS Current LiabilitesFEMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 12.35% over the past year.
  • FEMY shows a strong growth in Revenue. In the last year, the Revenue has grown by 63.54%.
  • Measured over the past years, FEMY shows a quite strong growth in Revenue. The Revenue has been growing by 11.86% on average per year.
EPS 1Y (TTM)12.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.33%
Revenue 1Y (TTM)63.54%
Revenue growth 3Y11.35%
Revenue growth 5Y11.86%
Sales Q2Q%31.35%

3.2 Future

  • Based on estimates for the next years, FEMY will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.28% on average per year.
  • Based on estimates for the next years, FEMY will show a very strong growth in Revenue. The Revenue will grow by 97.39% on average per year.
EPS Next Y33.6%
EPS Next 2Y24.9%
EPS Next 3Y18.64%
EPS Next 5Y15.28%
Revenue Next Year-2.37%
Revenue Next 2Y55.35%
Revenue Next 3Y100.14%
Revenue Next 5Y97.39%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
FEMY Yearly Revenue VS EstimatesFEMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
FEMY Yearly EPS VS EstimatesFEMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • FEMY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year FEMY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FEMY Price Earnings VS Forward Price EarningsFEMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FEMY Per share dataFEMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • FEMY's earnings are expected to grow with 18.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.9%
EPS Next 3Y18.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • FEMY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FEMASYS INC

NASDAQ:FEMY (2/23/2026, 8:00:00 PM)

After market: 0.5246 -0.03 (-4.62%)

0.55

+0.01 (+1.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-14
Earnings (Next)03-25
Inst Owners8.01%
Inst Owner Change151.12%
Ins Owners8.23%
Ins Owner Change4.38%
Market Cap32.16M
Revenue(TTM)2.06M
Net Income(TTM)-19.80M
Analysts82.22
Price Target5.27 (858.18%)
Short Float %4.08%
Short Ratio1.86
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.44%
Min EPS beat(2)18.3%
Max EPS beat(2)24.59%
EPS beat(4)2
Avg EPS beat(4)0.58%
Min EPS beat(4)-21.89%
Max EPS beat(4)24.59%
EPS beat(8)4
Avg EPS beat(8)-1.19%
EPS beat(12)6
Avg EPS beat(12)-1.81%
EPS beat(16)8
Avg EPS beat(16)2.91%
Revenue beat(2)0
Avg Revenue beat(2)-52.91%
Min Revenue beat(2)-55.12%
Max Revenue beat(2)-50.71%
Revenue beat(4)0
Avg Revenue beat(4)-60.47%
Min Revenue beat(4)-70.71%
Max Revenue beat(4)-50.71%
Revenue beat(8)0
Avg Revenue beat(8)-51.05%
Revenue beat(12)1
Avg Revenue beat(12)-38.6%
Revenue beat(16)3
Avg Revenue beat(16)-27.69%
PT rev (1m)0%
PT rev (3m)-8.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10%
EPS NY rev (1m)0%
EPS NY rev (3m)6.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.6
P/FCF N/A
P/OCF N/A
P/B 7.06
P/tB 7.27
EV/EBITDA N/A
EPS(TTM)-0.71
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.04
BVpS0.08
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -121.55%
ROE -434.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.05%
FCFM N/A
ROA(3y)-89.97%
ROA(5y)-77.42%
ROE(3y)-322.97%
ROE(5y)-238.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y-2.71%
F-Score2
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 158.29%
Cap/Sales 26.25%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.16
Quick Ratio 0.61
Altman-Z -13.3
F-Score2
WACC9.46%
ROIC/WACCN/A
Cap/Depr(3y)129.38%
Cap/Depr(5y)89.02%
Cap/Sales(3y)33.12%
Cap/Sales(5y)25.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.33%
EPS Next Y33.6%
EPS Next 2Y24.9%
EPS Next 3Y18.64%
EPS Next 5Y15.28%
Revenue 1Y (TTM)63.54%
Revenue growth 3Y11.35%
Revenue growth 5Y11.86%
Sales Q2Q%31.35%
Revenue Next Year-2.37%
Revenue Next 2Y55.35%
Revenue Next 3Y100.14%
Revenue Next 5Y97.39%
EBIT growth 1Y-1.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-81.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-79.49%
OCF growth 3YN/A
OCF growth 5YN/A

FEMASYS INC / FEMY FAQ

What is the ChartMill fundamental rating of FEMASYS INC (FEMY) stock?

ChartMill assigns a fundamental rating of 2 / 10 to FEMY.


What is the valuation status of FEMASYS INC (FEMY) stock?

ChartMill assigns a valuation rating of 0 / 10 to FEMASYS INC (FEMY). This can be considered as Overvalued.


Can you provide the profitability details for FEMASYS INC?

FEMASYS INC (FEMY) has a profitability rating of 1 / 10.